Treatment Algorithms for Early-Stage HR+ Breast Cancer
February 15th 2024Virginia Kaklamani, MD, joins Rohit Gosain, MD, and Rahul Gosain, MD, to discuss treatment paradigms for patients with early-stage HR+ breast cancer, highlighting the differences in treatment for premenopausal and postmenopausal patients.
Selecting Novel Small-Molecule Agents Vs Chemotherapy in KRAS G12C+ NSCLC
February 14th 2024Patients with KRAS G12C-mutated non–small cell lung cancer who have brain metastases or intolerability of intravenous infusion may be more suitable to receive a small molecule inhibitor compared with chemotherapy, says Sandip P. Patel, MD.
Insights into Strategies Using Concurrent Immunotherapy with Chemoradiotherapy
February 13th 2024Dr. Reddy offers expert insights on employing concurrent immunotherapy with chemoradiotherapy, discussing the approach's role and drawing from recent data, such as results from the KEYNOTE-799, PACIFIC-6, and DOLPHIN studies, to inform treatment strategies.
Managing Bleeding Risk in Patients with CLL on BTKi Therapy
February 7th 2024A panel of oncology experts review meta-analysis data evaluating bleeding risk with covalent BTKis, discuss the impact of these data on treatment decision making, and explore strategies in managing BTKi-related bleeding risk.
The Potential Role of Combination Adjuvant Immunotherapy in NSCLC
February 6th 2024A group of experts in oncology investigates the feasibility of combination adjuvant immunotherapy in NSCLC consolidation, assessing the utilization of multiple immune checkpoint inhibitors and scrutinizing the rationale, with a focus on findings from the COAST study and PACIFIC-8 studies.